<DOC>
	<DOCNO>NCT00697554</DOCNO>
	<brief_summary>The purpose study enroll pre-liver transplant patient vaccinate either novel adjuvanted HBV vaccine double dose Engerix™-B . The immunogenicity safety novel adjuvanted vaccine compare Engerix™-B control vaccine</brief_summary>
	<brief_title>Immunogenicity Safety Novel Adjuvanted HBV Vaccine Pre-liver Transplant Patients 18 Years Age</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female ≥ 18 year age time first vaccination . Written inform consent obtain subject . Seronegative antiHBsantibodies , antiHBcantibodies &amp; HBsAg . If subject female , must nonchildbearing potential , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Documented case liver failure , patient require eventual liver transplant Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Previous vaccination hepatitis B ( whether nonresponder vaccination ) . Previous vaccination adjuvant system contain MPL® . History hepatitis B infection . Known exposure hepatitis B virus within 6 week . Previously confirm human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . Immunosuppression cause administration parenteral steroid chemotherapy . Suspected confirmed multiple sclerosis subject ( applicable Centres 011 , 012 , 013 014/ France ) . History allergic disease reaction likely exacerbate component vaccine . Acute , intercurrent disease time enrollment . Oral/axillary temperature ≥ 37.5°C ( ≥ 99.5°F ) . Administration immunoglobulins and/or blood product within one month precede first dose study vaccine plan administration/ administration study period . Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Adjuvanted hepatitis B vaccine</keyword>
</DOC>